IC-MPGN clinical trials at UC Irvine

1 research study open to eligible people

Iptacopan in Participants With IC-MPGN
open to eligible people ages 12-60
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Orange, California and other locations

Last updated: January 31, 2025